Chiesi puts down $200M+ to col­lab­o­rate with Af­fi­body for res­pi­ra­to­ry dis­eases

The Ital­ian drug de­vel­op­er Chiesi will be look­ing to drop nine fig­ures to de­vel­op sev­er­al treat­ments for res­pi­ra­to­ry dis­eases in a deal with Swedish biotech Af­fi­body.

Chiesi and Af­fi­body will work to­geth­er on three pro­grams us­ing Af­fi­body’s mol­e­cules against three tar­gets. Chiesi will al­so fund the dis­cov­ery and de­vel­op­ment work as well as com­mer­cial­ize the can­di­dates world­wide, but Af­fi­body will hold on to co-pro­mot­ing the can­di­dates in the Nordic re­gion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER